AI in Biologics

Charlotte explains her new role as chief scientist at Exientia, focusing on the intersection of AI and biologics, particularly in developing antibody-based drugs. She emphasizes the potential of AI to enhance drug discovery processes, making them faster and more cost-effective while leveraging a range of computational techniques from standard statistics to advanced deep learning.